Skip to main content

Table 1 Patients’ characteristics (N = 125)

From: Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Median age at SCT (range) 53.6 years old (18–69)
Median follow-up (range) 21 months (3.3–146)
Interval between diagnosis and CR1 (range) 56.5 days (18–170)
Intervals from CR1 to SCT (range) 81.5 days (11–286)
Median year of SCT 2009 (2000–2013)
Secondary AML, N (%) 19 (15.2%)
CMV+ patient, N (%) 84 (68.3%)
CMV+ donor, N (%) 65 (68.3%)
Karnofsky >90% at SCT, N (%) 83 (70.3%)
Gender, N (%)
 Male 71 (57%)
 Female 54 (43%)
Donor type, N (%)
 Sibling 60 (48%)
 Unrelated 54 (43.2%)
 Cord blood 10 (8%)
Source of SC, N (%)
 BM 19 (15.2%)
 PB 95 (76%)
 CB 10 (8%)
Conditioning regimen, N (%)
 MAC 51 (41%)
 RIC 73 (59%)
In vivo T cell depletion, N (%) 64 (51%)
 ATG 47 (38%)
 Alemtuzumab 17 (14%)
Monosomal karyotype, N (%) 86 (82.7%)
Missing, N 21
Complex karyotype, N (%) 98 (90.7%)
Missing, N 17
Inv(3), N (%) 3 (2.9%)
Missing, N 20
-7, N (%) 41 (39%)
Missing, N 20
-5/5q-, N (%) 58 (55.2%)
Missing, N 20
Both -7 and -5/5q-, N (%) 28 (26.9%)
  1. Abbreviations; N number, CR1 first complete remission, SCT stem cell transplantation, AML acute myeloid leukaemia, CMV cytomegalovirus, BM bone marrow, PB peripheral blood, CB cord blood, MAC myeloablative conditioning, RIC reduced-intensity conditioning, ATG anti-thymocyte globulin